SOURCE-LINKED STUDY SUMMARY
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
Abstract summarizedQuality not appraised
- What was studied
- Randomized comparison of semaglutide with placebo for symptoms, physical limitations and weight in obesity-related heart failure.
- Who / model studied
- 616 people with obesity, type 2 diabetes and heart failure with preserved ejection fraction, treated for 52 weeks.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Both primary outcomes favored semaglutide: symptom/function scores improved 13.7 versus 6.4 points, and weight fell 9.8% versus 3.4%. For a confirmatory secondary outcome, walking-distance improvement was 14.3 meters greater than with placebo. Serious adverse events occurred in 17.7% versus 28.8%.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2313917